Abstract:

Abstract Objective：To estimate the efficacy and complications of peritoneal dialysis (PD) in patients with end stage renal disease (ESRD) to lupus nephritis (LN) and give some therapeutic advises. Methodology：Forty six ESRD lupus patients who started PD from July 2002 to December 2012 were involved in this retrospective cohort study, and 92 PD patients randomized from non-diabetic ESRD were regarded as control group. The two groups were matched by age, sex and eGFR at the beginning of PD. The follow-up time was more than 3 months. The data of hemoglobin, albumin, PD associated complications (catheter associated complications, infectious and non-infectious complications)，cause of drop-off and clinical outcomes were collected and analyzed. Result：The sexual ratios of the two groups were both 0.53 male to 1 female. The average age of LN and control group was 35.5±13.2 and 36.5±10.7 years.(P＞0.05). Before starting PD therapy, the concentration of hemoglobin and serum albumin in LN group was 8.1±1.9g/dl and 31.9±6.5g/l less than that in control group 8.9±1.6g/dl and 38.4±5.2g/l (p＜0.01). The incidence of peritonitis in LN group was obviously higher than that in control group (26.1% vs 6.5%, P＜0.05). There were no statistical differences of Kt/V and CCl between two groups. The mean duration time of PD in LN and control group was 4.4±15.8 and 22.5±16.9 months (p<0.05). The LN group had a higher mortality than that of control group. The most （75%）of LN patients with PD died of various infections including peritonitis, lung infection and septicemia. Patients in LN group suffered more severe infections and worsen outcomes. Catheter associated complications and non-infectious complications of the two groups had no significant difference. Conclusion：ESRD LN patients with PD suffered more infectious complications and had lower survival rate and technical survival rate, which can be attributed to lower serum albumin level and prescription of immune-suppressive drugs.

Key words: peritoneal dialysis, lupus nephritis, survival rate